Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Zugman

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Cancer Treatment and Research|August 23, 2025
Immunotherapy in Renal Cell CarcinomaMiguel Zugman, Salvador Jaime-Casas, Peter D Zang, et al.
Epilepsia|May 26, 2017
Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrationsPhilip N Patsalos, Miguel Zugman, Charlotte Lake, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 4, 2026
From Sequencing to Treatment: Operational Challenges in Translating Precision Oncology Into Clinical PracticeMiguel Zugman, Paulo V Campregher, Jeffrey S Ross, et al.
The Oncologist|February 6, 2025
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 studyMiguel Zugman, David F McDermott, Bernard J Escudier, et al.
JAMA Network Open|March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the USZeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
JCO Precision Oncology|May 18, 2026
Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing <i>ALK</i> Alteration Prolongs Treatment DurationVitor Abreu de Góes, Matthew Lee, Miguel Zugman, et al.
Cancer Research Communications|June 30, 2026
Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell TumorsHedyeh Ebrahimi, Ali Moradi, Regina Barragan-Carrillo, et al.
Clinical Genitourinary Cancer|August 21, 2025
Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical CystectomySalvador Jaime-Casas, Miguel Zugman, Regina Barragan-Carrillo, et al.
Frontiers in Oncology|October 23, 2025
Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinomaSalvador Jaime-Casas, Regina Barragan-Carrillo, Miguel Zugman, et al.
JCO Precision Oncology|April 10, 2025
Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung CarcinomaSalvador Jaime-Casas, Neal S Chawla, Nicholas J Salgia, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Cancer Treatment and Research|August 23, 2025
Immunotherapy in Renal Cell CarcinomaMiguel Zugman, Salvador Jaime-Casas, Peter D Zang, et al.
Epilepsia|May 26, 2017
Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrationsPhilip N Patsalos, Miguel Zugman, Charlotte Lake, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 4, 2026
From Sequencing to Treatment: Operational Challenges in Translating Precision Oncology Into Clinical PracticeMiguel Zugman, Paulo V Campregher, Jeffrey S Ross, et al.
The Oncologist|February 6, 2025
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 studyMiguel Zugman, David F McDermott, Bernard J Escudier, et al.
JAMA Network Open|March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the USZeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
JCO Precision Oncology|May 18, 2026
Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing <i>ALK</i> Alteration Prolongs Treatment DurationVitor Abreu de Góes, Matthew Lee, Miguel Zugman, et al.
Cancer Research Communications|June 30, 2026
Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell TumorsHedyeh Ebrahimi, Ali Moradi, Regina Barragan-Carrillo, et al.
Clinical Genitourinary Cancer|August 21, 2025
Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical CystectomySalvador Jaime-Casas, Miguel Zugman, Regina Barragan-Carrillo, et al.
Frontiers in Oncology|October 23, 2025
Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinomaSalvador Jaime-Casas, Regina Barragan-Carrillo, Miguel Zugman, et al.
JCO Precision Oncology|April 10, 2025
Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung CarcinomaSalvador Jaime-Casas, Neal S Chawla, Nicholas J Salgia, et al.
Pageof 3